Source: PubMed / Journal of the American College of Cardiology , Nov 2025
Although these establishments adhere to stringent regulations, the custom-compounded medications they produce are not endorsed by the FDA
Approximately 50% of Americans will be obese by 2030, and as more adults struggle with excess weight, medical weight loss programs with semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound) are becoming increasingly popular weight loss solutions
[DOI] [PubMed] [Google Scholar] 70.Snyder B., Polasek T.M., Doogue M.P
Teratogenic Effects There are no adequate and well-controlled studies in pregnant women
Abruptly stopping tirzepatide after months of use leads to rapid appetite return and weight regain in most people